Prime Highlights
- PureHealth has launched the Abu Dhabi Health Research Centre (ADHRC) to unify and manage its clinical research operations across Abu Dhabi.
- The centre aims to strengthen medical innovation by coordinating studies across hospitals, clinics, and laboratories with support from the Department of Health – Abu Dhabi.
Key Facts
- ADHRC oversees more than 100 active clinical studies and involves over 700 research professionals and 300+ principal investigators.
- It runs major programs like the “Longevity 2.0” trial with over 3,000 participants and focuses on fields such as oncology, neurology, and precision medicine.
Background
PureHealth has launched the Abu Dhabi Health Research Centre (ADHRC), a new clinical research division aimed at bringing all its research activities under one structure across Abu Dhabi.
The organisation announced the centre during the first ADHRC Research Conference 2025, held in the capital with support from the Department of Health – Abu Dhabi (DoH). The conference drew more than 350 participants from government bodies, universities, hospitals, and the life sciences sector.
PureHealth said the new centre will coordinate research across its healthcare network, covering 16 hospitals along with a large number of primary care clinics and specialised laboratories. ADHRC will manage the full clinical research process, including study planning, recruitment of trial participants, regulatory coordination, data handling, and publication of findings.
The centre also includes dedicated clinical trial units for both inpatient and outpatient research. PureHealth stated that it operates the largest outpatient clinical trial unit in the Middle East, with the ability to manage more than 800 patient trial visits each day.
ADHRC currently supports over 100 ongoing clinical studies and employs a research workforce of more than 700 professionals. More than 300 principal investigators are involved, along with over 2,500 doctors, specialists, and consultants working across key medical areas such as oncology, neurology, precision medicine, and artificial intelligence.
The centre is conducting research across 22 therapeutic areas and contributes to more than 400 scientific publications each year. Its focus includes personalised medicine, rare diseases, neuroscience and advanced cell and gene therapies. ADHRC also uses artificial intelligence and machine learning to analyse large datasets and improve the speed of medical discovery.
One of its major programmes is the Longevity clinical trial, which PureHealth described as the largest of its kind in the region. The second phase, Longevity 2.0, includes more than 3,000 participants and builds on earlier findings that showed a 2.2-year improvement in healthspan through lifestyle changes.
DoH officials said the centre strengthens Abu Dhabi’s ability to support high-quality medical research and improve healthcare outcomes.
